For researchers on the hunt for the genetic roots of disease, the cost of deep whole-genome sequencing makes it challenging ...

Clinical-stage biotech Alchemab Therapeutics has extended its series A financing with a £25 million (USD $34 million) investment from the British Business Bank - the Bank's largest investment in a ...

Julie Coletti "is a highly accomplished legal and business leader with deep experience across the life sciences and medical ...

Just over two decades ago, reading the complete human genome was considered one of the most ambitious scientific projects ever attempted. The international Human Genome Project took nearly 13 years ...

Aardaia will use the new funding to expand its crop breeding platform and accelerate the development of the aardaker, a ...

Agreement expands Active Motif's research genomics portfolio while supporting Arima's strategic focus on its clinical diagnostics platform ...

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical ...

Illumina, Inc. (NASDAQ:ILMN) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 26, Bernstein SocGen analyst Eve Burstein resumed coverage of Illumina, Inc.

When Roche previewed the Axelios technology in February, a Jefferies analyst called the next-generation sequencing platform the “greatest credible competitive threat in years.” ...

Caris Life Sciences ® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine ...

Blue Energy, GE Vernova, and Crusoe are advancing a gas-to-nuclear model that pairs natural gas with SMRs to deliver firm ...

Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies ...